Fig. 5: TEDs.
From: Pan-cancer whole-genome comparison of primary and metastatic solid tumours
a, Workflow representing the number of treatment groups in each step of the analysis. For the external layers of the pie chart, the number of treatments with identified TEDs is coloured by cancer type. For the internal layers of the pie chart, the category of the corresponding treatment is shown. n Refers to the number of treatment groups with at least one TED. MSS, microsatellite stable; TNB, triple negative breast cancer. b, Volcano plots displaying the identified TEDs. Each dot represents one cancer gene alteration type in one treatment group. The x axis displays the effect size (as log2(odds ratio)) and the y axis shows the significance (−log10(q value)). The circle markers denote TEDs exclusively mutated in the treatment group (squared makers are used otherwise). Markers are coloured according to the type of alteration. The thicker edge lines indicate known resistance drivers. CNA, copy number alteration; UTR, untranslated region. c, Global proportion of patients with TEDs treated for metastasis. d, Mean number of driver alterations per patient with a metastatic tumour before (purple circle) and after (purple square) excluding TEDs compared with patients with primary tumours (orange square). The vertical lines indicate s.d. The mean number of driver alterations are labelled. n Metastatic and n primary denote the number of metastatic and primary samples, respectively.
